Vaccine takes time for harvesting, quality testing can't be done overnight, says govt
The health ministry said the Centre is regularly interacting with national and international manufacturers like Pfizer, Moderna to make vaccines available in the country
Haven't abandoned states on Covid-19 vaccine: Niti Aayog's V K Paul
Companies, including Moderna and Pfizer, have said they will deal only with the Centre and not state governmentsIndia examining Pfizer's indemnity demand'
The govt will take a decision in the larger interest of people and on merit': VK Paul
Pursuing Pfizer, J&J; and Moderna since mid-2020 for vaccine imports: Govt
Facing accusations of delay in placing orders for vaccines, the government on Thursday defended its vaccine procurement policy saying it has been pursuing Pfizer, J&J and Moderna since mid-2020 for the earliest possible imports, and has even waived local trials for well-established foreign vaccine makers. "Buying vaccines internationally is not similar to buying 'off-the-shelf' items," the government said in a statement titled 'Myths & Facts on India's Vaccination Process'. The statement said the Central government has proactively eased entry of vaccines approved by USFDA, EMA, UK's MHRA and Japan's PMDA, and WHO's Emergency Use Listing into India in April. "These vaccines will not need to undergo prior bridging trials. The provision has now been further amended to waive off the trial requirement altogether for the well-established vaccines manufactured in other countries," it said. The statement said no application of any foreign manufacturer for approval is pending with the .
Pfizer Ltd - 500680 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) and other application regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agent of the Company, KFin Technologies Private Limited has received the requests for issue of duplicate Share Certificate(s) from the Shareholders. Pfizer Ltd - 500680 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In terms of Regulation 24(A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed, Secretarial Compliance Report for the year ended March 31, 2021, issued by Mr. K. G. Saraf, Practicing Company Secretary. We request you to kindly take the above on record. PFIZER LTD. - 500680 - Announcement under Regulation 30 (LODR)-Dividend Updates
We submit herewith audited financial results for the financial year endedMarch 31, 2021, Statement of Assets and Liabilities as on March 31, 2021, Statement of Audited Cash Flows for the year ended March 31, 2021, Declaration with respect to Audit Report with unmodified opinion and the Auditor's Report by Auditors,M/s. Walker Chandiok & Co LLP, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 2.15 p.m. and concluded at 4.00 p.m. Further, please be informed that the Board of Directors of the Company has recommended a normal dividend of Rs. 30/- per equity share of Rs. 10/- each (300%) and a special dividend of Rs. 5/- per equity share of Rs. 10/- each (50%), aggregating to total dividend of Rs. 35/- per equity share of Rs. 10/- each (350%) for the year ended March 31, 2021. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 15, 2021. PFIZER LTD. - 500680 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed press release for the Audited financial results for the quarter and year ended March 31, 2021. Please take the above on record. PFIZER LTD. - 500680 - Audited Financial Results And Audit Report For The Financial Year Ended March 31, 2021
We submit herewith audited financial results for the financial year ended March 31, 2021, Statement of Assets and Liabilities as on March 31, 2021, Statement of Audited Cash Flows for the year ended March 31, 2021, Declaration with respect to Audit Report with unmodified opinion and the Auditor's Report by Auditors, M/s. Walker Chandiok & Co LLP, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 2.15 p.m. and concluded at 4.00 p.m. Further, please be informed that the Board of Directors of the Company has recommended a normal dividend of Rs. 30/- per equity share of Rs. 10/- each (300%) and a special dividend of Rs. 5/- per equity share of Rs. 10/- each (50%), aggregating to total dividend of Rs. 35/- per equity share of Rs. 10/- each (350%) for the year ended March 31, 2021. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 15, 2021. PFIZER LTD. - 500680 - Corporate Action-Board approves Dividend
Please be informed that the Board of Directors of the Company has recommended a normal dividend of Rs. 30/- per equity share of Rs. 10/- each (300%) and a special dividend of Rs. 5/- per equity share of Rs. 10/- each (50%), aggregating to total dividend of Rs. 35/- per equity share of Rs. 10/- each (350%) for the year ended March 31, 2021. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 15, 2021.